...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
【24h】

Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.

机译：表皮生长因子之间的关系受体基因突变的严重性吉非替尼不良事件的患者先进的非小细胞肺癌。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: Recent reports have demonstrated that mutation of epidermal growth factor receptor (EGFR) gene is predictive factor for tumor responsiveness to gefitinib suggesting the importance of EGFR status for the treatment of the patients with non-small cell lung cancer (NSCLC). However, the relationship between EGFR mutation and adverse events of gefitinib is still unknown. The aim of this study was to evaluate its correlation. PATIENTS AND METHODS: Twenty-six tumor samples from Japanese NSCLC patients who received gefitinib in Okayama University Hospital between November 2000 and October 2004 were examined exons 18-21 of EGFR using direct sequence method. We retrospectively reviewed the clinical records and compared EGFR mutation status with adverse events during gefitinib treatment. RESULTS: Of all 26 patients, EGFR mutation (exon 19 in-frame deletion, 6; exon 21 L858R, 5), were detected in 11 patients (42.3%). The principal adverse event was skin rash (89%), diarrhea (39%), and liver injury (39%). Grade 3 or more adverse events were not common. EGFR mutation status was correlated with neither its frequency nor severity of adverse events during gefitinib treatment including skin rash, diarrhea, liver injury, and interstitial lung disease. As expected, objective response rate of those with EGFR mutations was significantly higher than those without EGFR mutations (78% versus 21%, P<0.001). CONCLUSION: Our study did not demonstrate the presence of close relationships between EGFR mutation status and adverse events during gefitinib treatment.
机译：目的:最近的报告显示表皮生长因子受体突变(EGFR)基因是肿瘤的预测因素吉非替尼暗示响应能力表皮生长因子受体状态治疗的重要性非小细胞肺癌患者(NSCLC)。突变和吉非替尼仍然是不良事件未知的。其相关性。从日本的非小细胞肺癌患者肿瘤样本在日本冈山大学医院接受吉非替尼2000年11月至2004年10月使用直接检查第18 - 21外显子的表皮生长因子受体序列的方法。相比临床记录和表皮生长因子受体突变吉非替尼期间状态与不良事件治疗。突变(外显子19在坐标系删除6;L858R 5),检测11例(42.3%)。主要的副反应是皮疹(89%),腹泻(39%),肝损伤(39%)。或更多的不良事件是不常见的。突变状态与也没有了不良事件的频率和严重程度吉非替尼治疗包括皮疹,腹泻,肝损伤和肺间质疾病。表皮生长因子受体突变明显高于那些没有表皮生长因子受体突变(78%和21%,P < 0.001)。不能证明存在密切的表皮生长因子受体突变状态和之间的关系吉非替尼治疗期间的不良事件。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号